key: cord-0760487-jvdtt6m4 authors: Catargi, Bogdan; Cheisson, Gaëlle; Tauveron, Igor; Jacqueminet, Sophie; Benhamou, Dan title: Diabetes care during the acute phase of infection in ICU patients with specific attention to COVID-19 outbreak date: 2020-06-17 journal: Anaesth Crit Care Pain Med DOI: 10.1016/j.accpm.2020.06.004 sha: 8e5337d46b5b1cab06c2df17a0e272163f120b00 doc_id: 760487 cord_uid: jvdtt6m4 nan Diabetes care during the acute phase of infection in ICU patients with specific attention to COVID-19 outbreak Diabetic patients, whether insulin-treated or not, have been reported to be at high risk for severe COVID-19 infection and many of them require to be admitted to an intensive care unit (ICU). In today's context of sanitary crisis, ICU physicians may encounter a large number of diabetic patients [1] and the present Guidelines are associated with practical sheets as it has been suggested that timely and standardised blood glucose management for diabetic patients with COVID-19 is urgently needed [2] . These sheets are presented very similarly to the previously published ones, which were devoted to blood glucose control in the perioperative period [1] [2] [3] , for both type 1 (T1D) and type 2 (T2D) diabetic patients ( Fig. 1) . Indeed, many similarities exist regarding glucose derangement occurring in the perioperative period (both before, during and after surgery) [4, 5] and glucose control impairment associated with viral infections requiring admission to ICU. It should be noted that the suggested rules are also valid for any diabetic patient admitted to ICU with an infection, and not restricted to COVID-19 viral infection. Several key points related to ICU care are presented below: viral infection and admission to an ICU represent a major stress period, and severe initial insulin resistance is common; blood glucose target in ICU: 5 to 10 mmol/L; intravenous insulin infusion should be used to target the same blood glucose range as in the perioperative period (see Fig. 2 ). Start continuous intravenous insulin infusion if two consecutive blood glucose measurements above 10 mmol/L in T2D or immediately after stopping an external insulin pump (basal flow) or a slow acting insulin treatment in T1D patients; non-insulin treatments (oral or injectable antidiabetic drugs) should be stopped in T2D patients; insulin should never be stopped in T1D patients (as it would lead to ketoacidosis); for patients on continuous subcutaneous insulin infusion (insulin pump) and admitted in the ICU, we strongly recommend to switch to continuous intravenous insulin administration, which is more easily handled by experienced ICU teams; more and more patients are equipped with continuous glucose monitoring devices: results obtained from the Abbott's Free Anaesth Crit Care Pain Med 39 (2020) 375-379 Style Libre 1 sensor and the Medtronic 1 glucose sensor can be distorted by high doses of vitamin C and high doses of paracetamol respectively. None of these sensors has been approved so far for use in ICU where anaemia and haematocrit changes can modify results; blood glucose measurement should use traditional methods for sampling and measurement (arterial > venous > capillary glucose strips and meters). Glucose sensors may be used as a complementary tool and assessments obtained between blood glucose measurements (information on the trend); glucose supply should be administered as soon as possible in ICU on Day 0 or Day 1, preferably using oral or enteral route. If enteral route is not available, consider intravenous glucose fluids ( 100 g glucose/day: for example, D10%W 40 mL/h) or parenteral nutrition; once food intake is started and insulin requirements become steady, continuous intravenous insulin infusion should be switched to a subcutaneous basal bolus schedule. A basal bolus schedule can be set in conjunction with enteral or parenteral feeding (Figs. 3 and 4) ; for T2D patients, resumption of previous antidiabetic treatment should be discussed according to the present clinical and biological status (kidney, heart and respiratory assessment) (Figs. 5 and 6); management to obtain optimal dosing of long acting insulin doses should rely on local diabetologists or mobile teams (at least two phone numbers should be provided), in order to define a therapeutic target, reduce strong blood glucose fluctuations and consider therapeutic education if insulin has to be continued after hospital discharge. diabetic ketoacidosis or hyperosmolar hyperglycaemic state can occur during infection. Please refer to sheet 6 for treatment Guidelines. Letter to the Editor / Anaesth Crit Care Pain Med 39 (2020) 375-379 378 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed working party approved by the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society for the study of Diabetes (SFD) working party approved by the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society for the study of Diabetes (SFD) working party approved by the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society for the study of Diabetes (SFD) Bogdan Catargi a , Gaë lle Cheisson b , Igor Tauveron a , Sophie Jacqueminet a a French Society for the study of Diabetes (SFD) Society of Anaesthesia and Intensive Care (SFAR), 75016 Paris, France *Corresponding author at: Service d'Anesthé sie Ré animation Mé decine Pé ri Opé ratoire The authors declare that they have no competing interest.